Screen Failure Analysis

The process of breaking down complex protocol criteria into atomic, independently evaluable logical components. Each criterion is parsed into its constituent parts—such as a specific lab value threshold, a temporal constraint, or a comorbidity exclusion—to enable precise failure attribution. This granular decomposition prevents the common problem of lumping multiple failure reasons under a single vague category, allowing sponsors to identify exactly which criterion is the primary driver of screen failures.

A structured taxonomy for classifying screen failures into actionable root cause categories rather than generic labels. Common categories include:

• Protocol Design Failure: Criteria that are overly restrictive or misaligned with the real-world patient population
• Data Availability Failure: Missing or incomplete patient data required to confirm eligibility
• Temporal Window Failure: Patient meets criteria but outside the protocol-specified time frame
• Concomitant Medication Failure: Exclusionary drug interactions identified during screening
• Biomarker Mismatch: Patient lacks the required molecular or genetic marker

The statistical measurement of screen failure rates (SFR) per criterion, per site, and per protocol version. This analysis calculates the proportion of pre-screened patients who fail on each specific criterion, revealing the primary failure drivers. A criterion with a 40% failure rate may indicate it is too restrictive, while a criterion with a 0% failure rate may be redundant. Site-level SFR comparison identifies underperforming sites that may require retraining or have access to a misaligned patient population.

A predictive analysis that simulates how proposed changes to eligibility criteria would affect the screen failure rate and the available patient pool. By adjusting a criterion's threshold—such as widening a lab value range or removing a comorbidity exclusion—sponsors can model the net effect on enrollment velocity before implementing a formal protocol amendment. This data-driven approach replaces intuition with evidence, reducing the cycle time for protocol optimization.

The comparative analysis of screen failure rates across investigative sites to identify outliers and best practices. A site with an anomalously high SFR may be misunderstanding the protocol, using inadequate pre-screening methods, or serving a fundamentally different patient demographic. Conversely, low-SFR sites may be applying criteria too loosely, risking protocol deviations. Benchmarking enables targeted site retraining and feasibility reassessment.

The reconstruction of the end-to-end screening pathway for failed patients to identify where and why they dropped out. This includes tracking the sequence of assessments—from initial pre-screening through full record review to final eligibility determination—and pinpointing the exact stage at which failure occurred. Journey mapping reveals bottlenecks such as delays in obtaining medical records or lab results that contribute to screen failures independent of clinical criteria.

A machine-processable definition of a clinical condition, expressed as a set of logical expressions and data queries. Screen failure analysis relies on these precise, executable definitions to determine why a patient's structured data did not satisfy the inclusion criteria. Analyzing failures often reveals that a phenotype definition is too narrow, missing patients with atypical presentations, or too broad, capturing patients who lack a critical confirmatory biomarker.

The automated extraction and structuring of complex free-text inclusion and exclusion requirements from clinical trial protocols. A primary root cause of screen failures is the misinterpretation of ambiguous criteria during manual review. Automated parsing creates a machine-readable, auditable logic tree, allowing analysis to pinpoint exactly which atomic criterion is the most common point of failure across a screened population.

The AI capability to interpret and validate time-dependent clinical constraints against a patient's longitudinal record. Screen failure analysis frequently identifies temporal logic failures as a hidden bottleneck. A patient may have the correct diagnosis but fail because the washout period was 13 days instead of 14, or a required therapy sequence occurred in the wrong order, a nuance easily missed without automated temporal reasoning.

An automated process that cross-references a patient's active medication list against a trial's prohibited medications. This is a leading cause of screen failures, often due to unstructured medication data in clinical notes. Systematic analysis of these failures can reveal overly restrictive exclusionary drug lists that do not impact trial safety, providing data-driven evidence to amend the protocol and widen the eligible pool.

The assignment of relative importance scores to individual inclusion and exclusion criteria. Screen failure analysis is transformed by weighting, moving from a binary pass/fail to a nuanced eligibility score. This allows recruitment teams to stratify failures by the criticality of the failed criterion, distinguishing between a hard safety exclusion and a minor, potentially waivable, protocol deviation.

An analysis that uses automated patient screening to estimate the number of potentially eligible subjects at a specific research site. Pre-study feasibility often overestimates recruitment potential. Retrospective screen failure analysis provides a ground-truth calibration of these models, revealing the true prevalence of complex, multi-factorial eligibility criteria in a real-world patient population and preventing underperforming site selection.